COMPLETE AND INCOMPLETE SPINAL CORD INJURY · PARAPLEGIA · TETRAPLEGIA
A physician-led, laboratory-verified treatment programme targeting the biological barriers to neurological recovery after spinal cord injury — tailored to injury level, completeness, chronicity and each patient’s individual clinical profile.
Request Medical ConsultationAbout the Condition
Spinal cord injury (SCI) occurs when trauma, compression or vascular disruption damages the spinal cord, interrupting neural signal transmission between the brain and the body. Depending on the level and severity of damage, this results in partial or complete loss of motor function, sensation and autonomic control below the injury site.
SCI is classified using the ASIA Impairment Scale (AIS). Complete injuries (AIS A) involve total loss of motor and sensory function below the neurological level of injury. Incomplete injuries (AIS B–D) retain varying degrees of preserved function. This distinction is clinically critical: complete and incomplete injuries carry fundamentally different prognoses. Incomplete injuries generally have greater potential for functional recovery, while complete injuries present a more challenging biological environment — though meaningful gains remain possible.
Even small improvements after SCI can transform daily life. A single AIS grade improvement — from AIS A to AIS B, or from AIS B to AIS C — can mean the difference between total dependence and partial independence, between no sensation and protective awareness, between catheter reliance and restored bladder signalling. In spinal cord medicine, marginal neurological gains translate to disproportionate functional impact.
Approximately 250,000–500,000 new spinal cord injuries occur worldwide each year. Conventional rehabilitation addresses compensation and adaptation. Our programme targets the biological substrate of the injury itself — glial scarring, demyelination, disrupted axonal connectivity and chronic neuroinflammation — with the objective of restoring function that standard approaches cannot reach.
Complete SCI (AIS A)
Total loss of motor and sensory function below the neurological level of injury. No sacral sparing. Represents the most severe classification. Recovery potential is more limited, but targeted cellular intervention can promote zone-of-partial-preservation expansion and partial restoration of autonomic function.
Incomplete SCI (AIS B–D)
Preserved sensory and/or motor function below the injury level, including sacral segments. AIS B retains sensation only; AIS C and D retain varying degrees of motor function. Incomplete injuries respond more robustly to regenerative intervention due to surviving neural pathways that can be reactivated and strengthened.
Cervical SCI (Tetraplegia)
Injury at C1–C8 affecting all four limbs, trunk and potentially respiratory function. Higher cervical injuries may require ventilatory support. Even one level of cervical motor recovery can restore critical hand function or independent breathing capacity.
Thoracic/Lumbar SCI (Paraplegia)
Injury at T1–L5 affecting the lower limbs, trunk stability, and bladder/bowel function. Upper limb function is preserved. Recovery goals focus on trunk control, standing ability, bladder/bowel independence and reduction of neuropathic pain.
Our program is individually adapted for all subtypes and all stages of progression.
Important: Each patient is accepted into the programme only after a comprehensive individual medical assessment, which evaluates injury level, AIS classification, time since injury, MRI findings and overall clinical profile.
We do not offer a cure for spinal cord injury. Our programme targets the biological barriers to recovery — glial scarring, chronic inflammation, demyelination and disrupted axonal connectivity — with the clinical objective of restoring measurable neurological and functional gains.
Clinical Outcomes
The following data are derived from structured observational analysis of patients treated at BioCells Medical between 2013 and 2025. All figures represent aggregated clinical registry outcomes with longitudinal follow-up. These are observational results — not randomised controlled trial data — and do not constitute a guarantee of therapeutic effect.
58
SCI patients treated since 2013
72%
measurable functional stabilisation on SCIM at 3–6 months
+11 pts
average SCIM score change at 6 months — vs. expected +2 pts natural progression
68%
sustained functional stability with average 2 years of follow-up
81%
showed improvement in one or more measured domains
70%
retained independence in basic activities of daily living (ADL) at 12 months
Motor (voluntary motor activation below injury, trunk stability, sitting balance)
72%
Speech & cognitive (communication, cognitive endurance during rehabilitation)
58%
Autonomic & sensory (return of sensation below injury level, bladder/bowel signalling, neuropathic pain)
78%
Quality of life (daily independence, sleep, emotional well-being)
66%
3–8 weeks
Initial neurological response
3–6 months
Clinically meaningful change
1–3 years onward
Long-term stability — continuous monitoring
Important: Outcomes depend on injury level, AIS classification, time since injury, patient age and individual biological response. Complete injuries (AIS A) generally show more modest gains than incomplete injuries (AIS B–D). Individual results may vary significantly.
Find out if our program can help in your specific case. The initial medical consultation is free and carries no obligation.
Request ConsultationPatient Stories
“I went from feeling nothing below the injury to feeling pressure in my lower abdomen. That changed my catheterisation schedule completely. My physiotherapist also found voluntary muscle activation in my left hip. I went from nothing to something, and psychologically that shifted everything.”
Patient
Complete SCI (T6, AIS A) · United Kingdom
Every case is assessed individually by our physician team. Request a consultation to discuss your specific situation with our physician team.
Request ConsultationPatient Cases
Documented treatment outcomes recorded by the BioCells Medical team after personalised regenerative medicine protocols.
The BioCells Program
Our SCI programme combines five biological components into a single personalised protocol. No two protocols are identical — each is constructed following a detailed medical evaluation of the patient’s injury characteristics, neurological status and clinical priorities.
Minimally invasive administration
Treatment is delivered by intravenous infusion or intrathecal injection — not surgical instruments. No spinal surgery, no implants.
No general anaesthesia
All procedures are performed under local anaesthesia or without anaesthesia entirely, eliminating anaesthetic risk.
No risk of immune rejection
MSCs are immunoprivileged: they express low levels of HLA-I, lack HLA-II and carry a minimal risk of rejection whether the protocol is autologous or allogeneic. Allogeneic MSC protocols do not require immunosuppression.
Targets the biological barriers to recovery
Our protocol addresses glial scarring, chronic neuroinflammation, demyelination and axonal disconnection — the biological reasons conventional rehabilitation reaches a plateau.
Applicable to chronic injuries
Unlike many experimental approaches limited to acute SCI, our protocol has demonstrated results in patients years after injury. Chronic SCI patients are not excluded from the programme.
Patients from around the world
We work with patients from around the world. Airport transfers, accommodation, visa support and multilingual coordination are included in every treatment programme.
What It Is
MSCs are multipotent regenerative cells with demonstrated immunomodulatory, anti-fibrotic and neuroprotective properties. They are the most extensively studied cell type in spinal cord injury research and have shown safety across hundreds of clinical trials worldwide.
How It Is Done
Cells are collected from the patient’s own bone marrow (autologous, approximately 3-5 ml under local anaesthesia) or sourced from a certified donor (allogeneic), depending on individual clinical indications. All cells are expanded, quality-controlled and tested in our certified Warsaw laboratory before administration.
Biological Mechanisms
How This Helps in Spinal Cord Injury
After SCI, a dense glial scar forms at the injury site, creating a physical and chemical barrier that prevents axons from reconnecting. MSCs directly address this by modulating the scar environment, reducing inhibitory molecule expression and providing neurotrophic support that enables surviving axons to extend through and around the lesion zone.
Your Medical Board
The exact combination, dosage, sequencing and delivery method of all five components is determined individually by our medical board for each patient. No two treatment protocols are identical. Your programme is constructed based on your specific injury level, AIS classification, time since injury, biological markers and clinical priorities.
Your protocol is designed individually. Speak with our medical team to understand what your personalised program would include.
Request ConsultationPatient Journey
Your case is reviewed remotely by our physician team. We assess your diagnosis, current ASIA classification, MRI findings, functional status and treatment goals. This consultation is free and carries no obligation.
A detailed review of all medical documentation including MRI, neurological examination records and rehabilitation history. Our medical board evaluates eligibility, confirms safety parameters and designs your personalised therapeutic protocol.
Your cells are collected, isolated, expanded and quality-tested in our certified Warsaw laboratory. Each batch receives a full traceability certificate. This stage typically takes 2–3 weeks.
Cells are delivered by intravenous infusion or targeted intrathecal administration — no surgery, no general anaesthesia. Airport transfers, accommodation and visa support are included in the programme for international patients.
Structured rehabilitation sessions with our specialist, adapted to your current neurological level and functional capacity. Protocols focus on activating and strengthening any emerging motor or sensory recovery. Available at our clinic or remotely coordinated with your local rehabilitation team.
Your dedicated coordinator monitors neurological status, tracks ASIA and SCIM assessments, provides clinical guidance and adjusts recommendations based on your recovery data. A medical-grade wearable bracelet supports continuous health tracking regardless of your location.
The first step is free. Request a medical consultation and our medical consultant will contact you within 24 hours.
Request ConsultationSafety Profile
Cellular therapy is considered safe when delivered under proper medical supervision and according to validated protocols. In our practice, the procedure is well-tolerated by the majority of SCI patients.
Temporary mild reactions — such as transient discomfort at the infusion site, mild headache following intrathecal delivery, slight fatigue or low-grade temperature — may occur in a minority of patients. These are typically short-lived and resolve within 24–48 hours.
A final medical assessment is performed on-site before every treatment session. If a patient’s status has changed, the programme may be temporarily modified or postponed for safety reasons.
All contraindications are evaluated individually. A contraindication in one clinical context does not necessarily preclude treatment in a different context — this is always determined by physician assessment.
Standard Contraindications
Active acute infection or fever
Active malignancy or ongoing chemotherapy / radiotherapy
Severe decompensated cardiac or renal failure
Pregnancy
Unstable spinal fracture requiring surgical fixation
Post-Treatment
Dedicated rehabilitation specialist
monitors neurological status, motor and sensory recovery, and overall well-being
Personalised rehabilitation programme
adapted to emerging recovery patterns and current functional capacity
Medical-grade wearable monitoring
continuous physiological data collection supporting clinical decision-making
Long-term coordinator support
proactive check-ins, clinical guidance and response to any changes in neurological status
Continued clinical access
our medical team remains available for ongoing reassessment and protocol adjustment
Neurological recovery after spinal cord injury follows a longer biological timeline than most patients expect. The post-treatment period is as medically important as the treatment itself. Cellular and axonal repair processes continue for an extended period, and structured monitoring ensures that emerging recovery is identified, supported and maximised through appropriate rehabilitation.
Get Started
If you or someone you care about is living with spinal cord injury, our medical team is available for a free, no-obligation medical consultation — based on your diagnosis, injury level, time since injury and individual clinical profile.
We review every inquiry personally. You will speak with a physician, not an administrator.
Submit your case online or by phone
Our medical consultant contacts you to review your documents
The medical board presents your personalised treatment plan
Request a Consultation
Tell us about your condition. Our medical consultant will contact you within 24 hours to review your documents.
Open Consultation FormMultilingual coordination — English, Italian, French, Russian, Polish
Evidence Base
Our clinical approach is informed by and consistent with published research in the field of regenerative medicine.
